Foresite Capital Management VI LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Foresite Capital Management VI LLC reported 12 stock positions worth $330.8 million. Its top holding was CG Oncology (CGON) at 27.9% of the portfolio, followed by Rapt Therapeutics (RAPT, 16.0%) and Alumis (ALMS, 12.5%). Compared with Q3 2025, it opened 3 new positions, sold out of 3, added to 2 and reduced 1. The biggest buy was a new position in Natera (NTRA) and the biggest sale an exit from Akero Therapeutics (AKRO).
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0002013341
- Portfolio Value
- $330.8M (Q4 2025)
- SEC Filing
- 0001104659-26-015412 ↗ filed Feb 17, 2026
Holdings Value
Holdings 12 stocks · $330.8M
| CGON CG Oncology Inc. | 27.88% | 2,221,474 | $92.2M | No change |
| RAPT Rapt Therapeutics Inc. | 16.00% | 1,562,500 | $52.9M | No change |
| ALMS Alumis Inc. | 12.53% | 4,247,670 | $41.5M | No change |
| CNTA Centessa Pharmaceuticals Ltd. | 10.31% | 1,364,019 | $34.1M | Add +3.8% |
| VSTM Verastem Inc. | 7.32% | 3,135,120 | $24.2M | Add +19.9% |
| DNLI Denali Therapeutics Inc. | 4.99% | 1,000,000 | $16.5M | No change |
| NTRA Natera Inc. | 4.66% | 67,356 | $15.4M | New |
| AGIO Agios Pharmaceuticals Inc. | 4.36% | 530,000 | $14.4M | New |
| KYMR Kymera Therapeutics Inc. | 3.44% | 146,332 | $11.4M | No change |
| ATAIBECKLEY INC | 3.40% | 2,750,000 | $11.2M | New |
| CRVS Corvus Pharmaceuticals Inc. | 3.21% | 1,381,233 | $10.6M | Reduce -20.2% |
| HNGE Hinge Health Inc. Class A | 1.90% | 135,000 | $6.3M | No change |
Portfolio Sells Q3 2025 → Q4 2025
Portfolio Buys Q3 2025 → Q4 2025
| NTRA Natera Inc. | New | 4.66% | +4.66 |
| AGIO Agios Pharmaceuticals Inc. | New | 4.36% | +4.36 |
| ATAIBECKLEY INC | New | 3.40% | +3.40 |
| VSTM Verastem Inc. | Add +19.9% | 7.32% | −1.60 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +3.8% | 10.31% | −2.00 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $642.6M | CGON, ALMS, SPTX, DNLI, CLDX |
| Q1 2026 | 17 | $460.3M | CGON, ALMS, CNTA, CRVS, DNLI |
| Q4 2025 | 12 | $330.8M | CGON, RAPT, ALMS, CNTA, VSTM |
| Q3 2025 | 12 | $258.9M | CGON, RAPT, CNTA, VSTM, ALMS |
| Q2 2025 | 20 | $177.9M | CGON, CNTA, AKRO, ALMS, RAPT |
| Q1 2025 | 14 | $182.5M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, AKRO |
| Q4 2024 | 14 | $224.4M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, BCAX |